A closer look at Eleven Bio's Q2 results

Eleven Biotherapeutics (EBIO) Q2 results: Revenues: $0.8M (+276.7%); Operating Expenses: $8.8M (+145.6%); Net Loss: ($8.1M) (-78.4%); Loss Per Share: ($0.51) (+85.2%); Quick Assets: $45.0M (+467.0%).

No financial guidance given.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs